Enfusion CFO sells $52,836 in stock to cover tax obligations

CHICAGO—In a recent transaction, Bradley Herring, Chief Financial Officer of Enfusion , Inc. (NYSE:ENFN), sold 4,645 shares of Class A Common Stock. The shares were sold at a weighted average price of $11.375, amounting to a total transaction value of $52,836. This sale was conducted to cover tax withholding obligations associated with the issuance of the shares and was not a discretionary trade by Herring. The transaction comes as Enfusion’s stock has shown strong momentum, with a 39.5% price return over the past six months, according to InvestingPro data.

The transaction, which occurred on March 5, leaves Herring with a remaining ownership of 324,689 shares in Enfusion. The shares were sold in multiple transactions, with prices ranging from $11.32 to $11.455 per share, near the company’s 52-week high of $11.80.

Enfusion, a provider of cloud-based investment management software, is headquartered in Chicago, Illinois. The company maintains strong financial health with a current ratio of 3.42 and has demonstrated solid revenue growth of 15.5% over the last twelve months. InvestingPro analysis reveals 12 additional key insights about Enfusion’s financial performance and market position.

In other recent news, Enfusion Inc. has released its fourth-quarter earnings report, providing investors with the latest insights into the company’s financial performance. The report coincides with the announcement of an acquisition agreement by Clearwater Analytics, which offers $11.25 per share for Enfusion. This acquisition price now serves as a benchmark for the company’s valuation, influencing recent analyst actions. Morgan Stanley (NYSE:MS) has downgraded Enfusion’s stock rating from Overweight to Equal-weight, citing the acquisition as a key factor, while also raising the price target to $11.25 to match the offer price.

Similarly, Stifel downgraded Enfusion from Buy to Hold and adjusted its price target to $11.25, aligning with the acquisition terms. The acquisition agreement is seen as a favorable outcome for shareholders, with analysts noting the premium over the previous market valuation. Stifel’s analysis suggests that the acquisition price is reasonable given Enfusion’s financial projections, and the chances of a higher competing bid are considered slim. Investors are closely watching these developments as the acquisition process unfolds, marking a significant transition for Enfusion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.